A new pharmaceutical company has recently established its presence in Tianhe district of Guangzhou, bringing a renewed impetus to its scientific and technological innovation.

With a registered capital of 3 million yuan ($414,303), Tisheng Biomedical Technology (Guangzhou) is poised to drive forward clinical research on T-cell receptor (TCR) protein drugs.

The company is set to work closely with hospitals in Guangzhou and its neighboring areas with clinical research qualifications to develop immune therapy approaches for Chinese patients with solid tumors.

A plaque bearing the name Tisheng Biomedical. [Photo/WeChat account: gztzth]

Founded in September 2021, the parent company Tisheng Biomedical is dedicated to developing globally competitive TCR drugs. Its first product is scheduled to submit a clinical Investigational New Drug (IND) application to regulatory agencies in the United States and China in 2025.

Li Yi, the brain behind Tisheng Biomedical, stands as a pioneer in global TCR drug development. Having held the position of protein engineering director at Immunocore in the United Kingdom, he is the mastermind behind Kimmtrak, the sole TCR fusion protein drug available today.

Explaining their decision to select Tianhe, Xing Feng, CEO of Tisheng Biomedical, highlighted, "Tianhe stands out as the central district of Guangzhou, offering advanced higher education, a concentration of skilled professionals, and extensive top-tier healthcare services, creating an ideal setting for the research and clinical trials of biopharmaceutical firms".

Currently, Tianhe hosts more than 1,000 medical establishments, representing roughly a quarter of the total within Guangzhou.